186 related articles for article (PubMed ID: 36059526)
1. Neuroimaging and clinicopathological differences between tumefactive demyelinating lesions and sentinel lesions of primary central nervous system lymphoma.
Sun C; Han J; Lin Y; Qi X; Li C; Liu J; Qiu F
Front Immunol; 2022; 13():986473. PubMed ID: 36059526
[TBL] [Abstract][Full Text] [Related]
2. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
[TBL] [Abstract][Full Text] [Related]
3. Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions.
Lu SS; Kim SJ; Kim N; Kim HS; Choi CG; Lim YM
AJR Am J Roentgenol; 2015 Apr; 204(4):827-34. PubMed ID: 25794073
[TBL] [Abstract][Full Text] [Related]
4. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
Kim DS; Na DG; Kim KH; Kim JH; Kim E; Yun BL; Chang KH
Radiology; 2009 May; 251(2):467-75. PubMed ID: 19261924
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of pathological characteristics of acute and chronic cerebral tumefactive demyelinating lesions].
Sun C; Liu J; Gui Q; Lu D; Qi X
Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(45):3557-61. PubMed ID: 25622833
[TBL] [Abstract][Full Text] [Related]
6. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
[TBL] [Abstract][Full Text] [Related]
7. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmà I; Vivancos J
J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Demyelinating Lesions: True Sentinel Lesion or Immune-Mediated Response to Lymphoma?
Qiu T; Chanchotisatien A; Qin Z; Wu J; Chu S
World Neurosurg; 2021 Jan; 145():172-177. PubMed ID: 32949800
[TBL] [Abstract][Full Text] [Related]
9. Tumefactive demyelinating lesions versus CNS neoplasms, a comparative study.
Chew SH; Achmad Sankala HB; Chew E; Md Arif MHB; Mohd Zain NR; Hashim H; Koya Kutty SB; Chee YC; Mohd Saleh NB; Ong BH; Viswanathan S
Mult Scler Relat Disord; 2023 Nov; 79():104992. PubMed ID: 37717306
[TBL] [Abstract][Full Text] [Related]
10. Imaging features (CT, MRI, MRS, and PET/CT) of primary central nervous system lymphoma in immunocompetent patients.
Cheng G; Zhang J
Neurol Sci; 2019 Mar; 40(3):535-542. PubMed ID: 30580380
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of tumefactive demyelinating lesions and glioma by clinical presentations and neuroimaging studies].
Liu J; Qiao W; Zheng K; Zhao H; Qian H; Yao S; Duan F; Qiu F; Qi X
Zhonghua Yi Xue Za Zhi; 2014 Oct; 94(39):3047-51. PubMed ID: 25549675
[TBL] [Abstract][Full Text] [Related]
12. Clinical spectrum and prognosis of pathologically confirmed atypical tumefactive demyelinating lesions.
Zhang Y; Zhang T; Zhang X; Yan X; Lei J; Liu R; Yang Y; Zhang C; Zhang J; Zhang Y; Yue W
Sci Rep; 2023 May; 13(1):7773. PubMed ID: 37179394
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions.
Cha S; Pierce S; Knopp EA; Johnson G; Yang C; Ton A; Litt AW; Zagzag D
AJNR Am J Neuroradiol; 2001; 22(6):1109-16. PubMed ID: 11415906
[TBL] [Abstract][Full Text] [Related]
14. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
Jain RS; Khan I; Kandelwal K; Desai T
Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
[TBL] [Abstract][Full Text] [Related]
15. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
[TBL] [Abstract][Full Text] [Related]
16. The value of convolutional neural networks-based deep learning model in differential diagnosis of space-occupying brain diseases.
Miao X; Shao T; Wang Y; Wang Q; Han J; Li X; Li Y; Sun C; Wen J; Liu J
Front Neurol; 2023; 14():1107957. PubMed ID: 36816568
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology.
Kobayashi M; Shimizu Y; Shibata N; Uchiyama S
J Neurol; 2014 Oct; 261(10):1902-10. PubMed ID: 25034274
[TBL] [Abstract][Full Text] [Related]
18. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
[TBL] [Abstract][Full Text] [Related]
19. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
[TBL] [Abstract][Full Text] [Related]
20. Proton MR spectroscopy of tumefactive demyelinating lesions.
Saindane AM; Cha S; Law M; Xue X; Knopp EA; Zagzag D
AJNR Am J Neuroradiol; 2002 Sep; 23(8):1378-86. PubMed ID: 12223381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]